| 000 | 01878 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516033815.0 | ||
| 264 | 0 | _c20110914 | |
| 008 | 201109s 0 0 eng d | ||
| 022 | _a1473-5571 | ||
| 024 | 7 |
_a10.1097/QAD.0b013e328347f7e9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRamautarsing, Reshmie A | |
| 245 | 0 | 0 |
_aThai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. _h[electronic resource] |
| 260 |
_bAIDS (London, England) _cJun 2011 |
||
| 300 |
_a1299-303 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfectious Disease Transmission, Vertical _xprevention & control |
| 650 | 0 | 4 | _aLopinavir |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aPregnancy Complications, Infectious _xdrug therapy |
| 650 | 0 | 4 | _aPregnancy Outcome |
| 650 | 0 | 4 | _aPregnancy Trimester, Third |
| 650 | 0 | 4 |
_aPyrimidinones _xadministration & dosage |
| 650 | 0 | 4 |
_aRNA, Viral _xdrug effects |
| 650 | 0 | 4 |
_aRitonavir _xadministration & dosage |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _avan der Lugt, Jasper | |
| 700 | 1 | _aGorowara, Meena | |
| 700 | 1 | _aKerr, Stephen J | |
| 700 | 1 | _aBurger, David | |
| 700 | 1 | _aRuxrungtham, Kiat | |
| 700 | 1 | _aPhanuphak, Praphan | |
| 700 | 1 | _aChaithongwongwatthana, Surasith | |
| 700 | 1 | _aAvihingsanon, Anchalee | |
| 700 | 1 | _aPhanuphak, Nittaya | |
| 773 | 0 |
_tAIDS (London, England) _gvol. 25 _gno. 10 _gp. 1299-303 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/QAD.0b013e328347f7e9 _zAvailable from publisher's website |
| 999 |
_c20781103 _d20781103 |
||